AbbVie Inc. (ABBV) is a research-based biopharmaceutical company that develops, manufactures, and sells pharmaceuticals worldwide. The company witnessed strong momentum for its key immunology assets, Skyrizi and Rinvoq. This performance, combined with continued strength in its diverse portfolio, has helped the company mitigate the impact of the economic headwinds and deliver solid results in the third quarter.
ABBV’s steady performance has allowed it to raise its dividend payments consistently over the past nine years. ABBV’s board of directors recently declared an increase in its quarterly cash dividend from $1.41 per share to $1.48 per share, payable on February 15, 2023. This reflects an increase of nearly 5%.
